AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2024

Jun 20, 2024

33148_dirs_2024-06-20_669e9216-289e-40d8-a49c-28068529cc83.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2024-06-13

Reporting Person: GRANADILLO PEDRO P (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-13	Stock Option (Right to Buy)	$22.86	A	23944	Acquired	2034-06-13	Common Stock (23944)	Direct
2024-06-13	Stock Option (Right to Buy)	$22.86	A	4655	Acquired	2034-06-13	Common Stock (4655)	Direct

Footnotes

F1: This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025.

F2: This option represents a right to purchase a total of 4,655 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. This option was issued to the Reporting Person in lieu of director retainer fees of $70,000.